Part D

Part D

Ensuring a Robust Medicare Drug Benefit

Schaeffer researchers study Part D’s impact on formulary and benefit design, patient costs, innovation and overall health, with a focus on ensuring Medicare beneficiaries can access the high-value medications they need.

Cost Sharing for Preferred Branded Drugs in Medicare Part D

Stand-alone Part D plans increasingly use coinsurance rather than copayments for preferred brand drugs. This shift exposes beneficiaries to rising list prices, while rebates accrue to their plans.

Drug Pricing
Medicare

Featured Experts: Erin Trish

In The News View All

Part D

Ensuring a Robust Medicare Drug Benefit

Related Topics

Top Stories View All

Cost Sharing for Preferred Branded Drugs in Medicare Part D

Medicare Beneficiaries Face Much Higher Drug Costs as Plans Quickly Shift to Coinsurance

Comments to CMS on Proposed $2 Drug List Model

Most Medicare Beneficiaries Do Not Compare Prescription Drug Plans – And May Be Sticking with Bad Plans

In The News View All

Medicare Drug Price Negotiations Need Something New: A Floor

Trish explains why some insurers are prioritizing MA over Part D

The first round of Medicare drug price negotiations had modest impact, Joyce says

Increased plan restrictions on drugs raise concerns the policies may hurt patient health, Joyce says

Trish explains why Medicare spent $2.6 billion more on generics than Costco

Featured Research

Reforming the Medicare Part D Benefit Design: Financial Implications for Beneficiaries, Private Plans, Drug Manufacturers, and the Federal Government